

ID	Gene	Type	VAF	Amino Acid Change	Nucleotide Change	Chromosome	StartPosition	Coverage	TotalCoverage	RefCoverage	AltCoverage	Variant Assessment
1	DNMT3A	Frameshift	12.2%	p.W860Nfs*22	NM_022552.4:c.2577_2578msAA	2	25458595	869	763	106		This frameshift alteration has not been previously reported to our knowledge, but it is expected to be pathogenic.
2	TE12	Stop gained	18.5%	p.L882*	NM_001127208.2:c.2581T>A	4	106157684	969	789	180		This frameshift alteration has not been previously reported to our knowledge, but it is expected to be pathogenic.
3	ASXL1	Stop gained	5.4%	p.E865*	NM_015338.6:c.2593G>T	20	31023108	1307	1237	70		This frameshift alteration has not been previously reported to our knowledge, but it is expected to be pathogenic.
4	TERT	Promoter	9.0%	promotor c.-124C>T	NM_198253.3:c.-124C>T	5	1295228	343	312	31		MedGen UID: 1389413
5	TP53	Missense	8.40%	p.R248W	NM_000546.5:c.742C>T	17	7577539	869	769	73		COSMIC ID: COSV/5266205
	FGFR2	Missense	6.9%	G552R	NM_000141.4:c.1654G>A	10	123258027	538	500	38		This missense variant, located in the protein kinase domain, has not been previously reported or functionally characterized in the scientific literature to our knowledge. Therefore, its clinical significance is uncertain.
6	TE12	Stop gained	29%	p.W1847*	NM_001127208.2:c.5541G>A	4	106197208	1304	926	378		COSMIC ID: COSV/54399228
	KMT2D	Frameshift	32%	p.E4438Gfs*45	NM_003482.3:c.13313_13323del	12	49425164	1362	926	436		This missense alteration has not been previously reported or functionally characterized in the scientific literature to our knowledge. Therefore, its clinical significance is uncertain.
7	TE12	Missense	8.8%	p.H1881R	NM_001127208.2:c.5642A>G	4	106197309	1019	929	90		COSMIC ID: COSV/54397947
8	STAT3	Missense	21.9%	p.Y640F	NM_138276.2:c.1919A>T	17	40474482	914	714	200		COSMIC ID: COSV/52892807
9	IDH2	Missense	1.4%	p.R140Q	NM_002168.3:c.419G>A	15	90631934	651	451	10		COSMIC ID: COSV/57468751
	DNMT3A	Missense	15.2%	p.G654V	NM_022552.4:c.1961G>T	2	25464552	929	787	142		This missense alteration has not been previously reported or functionally characterized in the scientific literature to our knowledge. Therefore, its clinical significance is uncertain.
10	PPM1D	Frameshift	16.1%	p.F534*	NM_003620.4:c.1599_1611del	17	58740692	1273	1068	205		This missense alteration has not been previously reported or functionally characterized in the scientific literature to our knowledge. Therefore, its clinical significance is uncertain.
11	TP53	Missense	9.3%	p.Y234C	NM_000546.5:c.701A>G	17	7577580	503	456	47		COSMIC ID: COSV/52661201
12	PPM1D	Stop gained	6.30%	p.R552*	NM_003620.4:c.1654C>T	17	58740749	1178	1104	74		COSMIC ID: COSV/59964404
13	IDH1	Missense	1.0%	p.R132H*	NM_005896.3:c.395G>A	2	209113112	668	661	7		COSMIC ID: COSV/61615239
14	ASXL1	Frameshift	19.1	p.G646Vfs*12	NM_015338.6:c.1934dup	20	31022441	1240	1003	237		COSMIC ID: COSV/61012155
	UZAF1	Missense	25.40%	p.Q157P	NM_006158.2:c.470A>C	21	44514777	7221	538	183		COSMIC ID: COSV/52341120
15	DNMT3A	Missense	9.0%	G688R	NM_022552.4:c.2053G>A	2	25464460	781	711	70		COSMIC ID: COSV/53038183
16	PTEN	Missense	7.00%	P354L	NM_000314.8:c.1061C>T	10	88725078	781	711	55		COSMIC ID: COSV/64294840
17	IDH2	Missense	11.0%	p.R140Q	NM_002168.3:c.419G>A	15	90631934	839	736	76		COSMIC ID: COSV/57468751

Supplemental Table 2: Nonsynonymous alterations seen in non-WTC exposed firefighter controls responders: A total of 19 mutations were seen in 16 subjects.

Supplemental Table 3: Blood counts in WTC-exposed first responders: Presence of mutations does not appear to correlate with cytopenias as both groups have no significant cytopenias. 481 cases with available blood counts were included in analysis.

	Mutation Negative Cohort Median (Q1, Q3) (N=433)	Mutation Positive Cohort Median (Q1, Q3) (N=48)
Hemoglobin (g/dL)	14.8 (14.2, 15.4)	14.7 (13.8, 15.6)
Platelets (k/uL)	218.0 (175.5, 256.0)	221.5 (170.5, 259.0)
WBC (k/uL)	6.1 (5.0, 7.6)	6.8 (5.4, 7.9)
Neutrophil Count (k/uL)	3718.0 (2952.0, 4802.0)	4246.0 (3157.5, 5462.5)

n=1 participant without a mutation were missing platelet counts

Supplemental Table 4: Antibodies used for FACS analysis.

Antibody-Fluorophore	Clone	Final Dilution
Gr1 - PE	RB6-8C5	1:100
CD4 - PE-Cy5	GK1.5	1:100
CD8 α - PE-Cy5	53-6.7	1:100
B220 - PE-Cy5	RA3-6B2	1:100
CD19 - PE-Cy5	eBio1D3	1:100
Ter119 PE-Cy5	TER-119	1:100
Sca1 – BV421 (PB)	D7	1:100
c-kit - APC	2B8	1:100
CD34 - FITC	RAM34	1:100
Fc γ R II/III (CD16/32) – PE-Cy7	93	1:100